Stakeholders Comment Again on 340B Pricing and Manufacturer Penalty Regulation

by Admin | May 26, 2016 1:18 pm

May 26, 2016—Sixty-nine stakeholders have submitted comments online to the Health Resources and Services Administration about its proposed rule setting standards for calculating 340B ceiling prices and implementing civil monetary penalties for drugmakers that knowingly and intentionally overcharge for 340B drugs. The drug industry is adamant that HRSA drop its 340B penny pricing regime. Providers heartily disagree.  

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2016/05/stakeholders-comment-again-on-340b-pricing-and-manufacturer-penalty-regulation/

Copyright ©2024 340binformed.org unless otherwise noted.